Épisodes

  • Daily, Fri 20 Nov: Good fences make good neighbours? Washington's warning on China drug deals
    Nov 20 2026

    A US congressional commission says licensing deals are sending money and know-how to Chinese biotechs. The same week, a Boston investor opened in Shanghai, and Novartis showcased a blood-pressure drug that started in Shanghai. The National Security Commission on Emerging Biotechnology analysed 57 deals between 15 of the biggest drugmakers in the US market and 42 Chinese biotechs from January 2023 to October 2026, and supports a proposed US Treasury outbound-investment rule under the COINS Act (comments close 7 December). Plus AbbVie's $40 million upfront for Cologne's DISCO Pharmaceuticals, set against the $650 million it paid in January for RemeGen's (荣昌生物) clinical-stage RC148 (not like-for-like); QCZ484 on Novartis's investor-day stage, which Argo Biopharma (舶望制药) says came from Argo in Shanghai under a licensing deal; Merck's research deal with Isomorphic Labs; a reported Sanofi look at Insmed; and a closed-loop brain stimulator for depression.

    Full transcript and all sources for this episode

    Both voices are AI-cloned. Basil Lui (X: @basillui) is the real person behind the show; Ning is an AI co-host. Personal views, not investment or medical advice. Basil has no personal holding in any company mentioned.

    Weekly roundup: subscribe to The East-West Bio Brief newsletter on LinkedIn

    Chapters
    0:00 Intro and AI-voice disclosure
    1:06 The commission's warning: 57 deals, earlier and bigger
    3:58 The counterpoint: RA Capital's door in Shanghai
    4:30 The price of early science: AbbVie, RemeGen and Starna
    5:55 Quick hits: Novartis, Merck, Sanofi
    8:33 Beyond biotech: a closed-loop brain stimulator
    9:03 What to watch and sign-off

    Key sources: NSCEB: 'Innovated in China: The PRC's Progress Towards Capturing the U.S. Pharmaceutical Market' (18 Nov 2026) · NSCEB: 'China is Closing the Biopharma Innovation Gap' (19 Nov 2026) · South China Morning Post: RA Capital opens Shanghai office (19 Nov 2026)

    Also listen on: Apple Podcasts · Amazon Music · YouTube

    Afficher plus Afficher moins
    10 min
  • Daily, Thu 19 Nov: If you can't beat them, license them? Pfizer's $330M CAR-T bet on China
    Nov 18 2026

    A day after Pfizer's CEO named Chinese biotechs as his main competition by 2030, Pfizer agreed to pay a Suzhou company $330 million upfront for CAR-T made inside the body. Starna Therapeutics (星锐医药) licensed Pfizer three early in vivo CAR-T programmes for autoimmune disease outside Greater China, with up to $2.3 billion more in milestones plus royalties. Plus the FDA's published letter on Akeso's (康方生物) ivonescimab, which says 93% of the progression-free survival events in its key trial came from patients in China; Insilico Medicine's four months from candidate to first human for a non-opioid pain drug; Merck stopping nemtabrutinib; and GSK's Nelkarmi approval in ALK-positive lung cancer.

    Full transcript and all sources for this episode

    Both voices are AI-cloned. Basil Lui (X: @basillui) is the real person behind the show; Ning is an AI co-host. Personal views, not investment or medical advice. Basil has no personal holding in any company mentioned.

    Weekly roundup: subscribe to The East-West Bio Brief newsletter on LinkedIn

    Chapters
    0:00 Intro and AI-voice disclosure
    1:07 Pfizer and Starna: CAR-T made inside the body
    4:36 The ivonescimab letter: more than the survival miss
    6:23 Quick hits: Insilico, Merck, Nelkarmi
    8:57 What to watch and sign-off

    Key sources: Pfizer: exclusive licensing agreement with Starna Therapeutics (18 Nov 2026) · FDA: complete response letter database (BLA 761524, ivonescimab) · Insilico Medicine: ISM9528 first-in-human dosing (HKEX, 17 Nov 2026) · Merck: update on the BELLWAVE programme (17 Nov 2026)

    Also listen on: Apple Podcasts · Amazon Music · YouTube

    Afficher plus Afficher moins
    10 min
  • Daily, Wed 18 Nov: Software eats the world, really? A $5B bet on AI-designed drugs
    Nov 17 2026

    Andreessen's 2011 line meets a $5 billion bet on AI-designed medicines, before a single human trial. Isomorphic Labs, the London-based AI drug-design company spun out of Google DeepMind, raised $5 billion, with Singapore's Temasek among its existing backers, while two of the five AI drug-discovery companies with drugs in Phase 3 are running those trials in China. Plus South Korea's AriBio and its once-daily Alzheimer's pill AR1001, with Fosun Pharma (复星医药) weighing its option; AstraZeneca's Klygefa for generalised myasthenia gravis, which Japan approved first; quick hits on Roche's Wilserdly, Takeda's Innovent-discovered (信达生物) stomach-cancer drug, Akeso's (康方生物) gumokimab and OBI Pharma's Novartis deal; and wearables that want to treat you, not just track you, from Oura to Huawei and Samsung.

    Full transcript and all sources for this episode

    Both voices are AI-cloned. Basil Lui (X: @basillui) is the real person behind the show; Ning is an AI co-host. Personal views, not investment or medical advice. Basil has no personal holding in any company mentioned.

    Weekly roundup: subscribe to The East-West Bio Brief newsletter on LinkedIn

    Chapters
    0:00 Intro and AI-voice disclosure
    0:50 Isomorphic: $5B, no patient yet
    2:37 A Korean Alzheimer's pill, a Chinese option
    4:43 Klygefa: Japan said yes first
    6:47 Quick hits: Wilserdly, Takeda, Akeso, OBI
    8:31 Wearables that want to treat you
    9:45 What to watch and sign-off

    Key sources: Isomorphic Labs: Series C investment round (17 Nov 2026) · AriBio: POLARIS-AD Phase 3 topline results (16 Nov 2026) · AstraZeneca: Klygefa (gefurulimab) approved in the US (16 Nov 2026) · Roche: FDA approves Wilserdly (giredestrant) (16 Nov 2026)

    Also listen on: Apple Podcasts · Amazon Music · YouTube

    Afficher plus Afficher moins
    11 min
  • Daily, Tue 17 Nov: Eyes East: why J&J bet $2.2B on an eye drug discovered in China
    Nov 16 2026

    Johnson & Johnson is buying Ollin Biosciences for $2.2 billion upfront, and Ollin's lead drug, OLN324 for wet age-related macular degeneration and diabetic macular edema, was discovered in China by Innovent (信达生物). Is this how more of China's medicines will reach the West? We look at the NewCo route and the evidence test still ahead, then AI Brief's scorecard of AI-discovered drugs that have reached Phase 3, two of them running their Phase 3 trials in China: Insilico Medicine's (英矽智能) rentosertib for idiopathic pulmonary fibrosis and MindRank's (德睿智药) MDR-001 pill for obesity and type 2 diabetes. Plus Flagship Pioneering's new £100 million London lab and its Singapore hub, why Pennsylvania, Singapore and China start colorectal cancer screening at different ages, and Synchron's paused brain-implant trial.

    Full transcript and all sources for this episode

    Both voices are AI-cloned. Basil Lui (X: @basillui) is the real person behind the show; Ning is an AI co-host. Personal views, not investment or medical advice. Basil has no personal holding in any company mentioned.

    Weekly roundup: subscribe to The East-West Bio Brief newsletter on LinkedIn

    Chapters
    0:00 Intro and AI-voice disclosure
    0:44 J&J, Ollin and a drug from Suzhou
    3:11 The AI drug race: five in Phase 3
    6:20 Flagship: London lab, Singapore hub
    8:12 Colorectal screening: what age?
    10:26 Synchron pauses its US trial
    11:01 What to watch and sign-off

    Key sources: Johnson & Johnson: to acquire Ollin Biosciences (16 Nov 2026) · Innovent: HKEX announcement on OLN324 / IBI324 (16 Nov 2026) · AI Brief: AI drug discovery companies ranked · Flagship Pioneering: Origination Lab in London (16 Nov 2026)

    Also listen on: Apple Podcasts · Amazon Music · YouTube

    Afficher plus Afficher moins
    12 min
  • Weekly, Mon 16 Nov: The FDA says "not yet" to a Chinese cancer drug. What changed?
    Nov 15 2026

    The FDA has sent Summit Therapeutics a complete response letter for ivonescimab, the lung cancer drug invented in China by Akeso (康方生物): progression-free survival was met, overall survival was not. Is that a no to China or a no to the evidence? We weigh the global HARMONi trial against the China-only HARMONi-A survival win, the FDA's record of about a dozen China-invented approvals, and what the survival bar means for Biokin's (百利天恒) iza-bren and Hengrui's (恒瑞医药) EGFR lung-cancer ADCs. Plus Shanghai's findings after a child died in a brain gene-editing study, WuXi AppTec (药明康德) coming off the US 1260H list ahead of December's BIOSECURE list, Moderna and Merck's personalised mRNA filing plan, Vir's hepatitis delta win while Brii's (腾盛博药) China rights stay frozen, and the FDA's new NAION warning for GLP-1 drugs. Each segment links back to this week's dailies.

    Full transcript and all sources for this episode

    Both voices are AI-cloned. Basil Lui (X: @basillui) is the real person behind the show; Ning is an AI co-host. Personal views, not investment or medical advice. Basil has no personal holding in Moderna.

    Chapters
    0:00 Intro and AI-voice disclosure
    1:20 Ivonescimab: a no to the evidence, not to China
    6:33 EGFR lung-cancer ADCs: iza-bren and Hengrui
    8:49 Shanghai: speed versus safeguards
    13:06 WuXi AppTec and the BIOSECURE list
    14:43 Moderna and Merck's mRNA filing plan
    16:36 Vir and Brii: a frozen territory
    17:43 GLP-1s and the NAION warning
    19:32 What changed? and sign-off

    Key sources: Summit Therapeutics: update regarding ivonescimab BLA (15 Nov 2026) · Fierce Pharma: FDA rejects Summit, Akeso's ivonescimab · Xinhua: Shanghai gene-editing investigation bulletin (13 Nov 2026) · FDA: GLP-1 safety labeling changes for NAION (9 Nov 2026)

    Weekly LinkedIn newsletter

    Also listen on: Apple Podcasts · Amazon Music · YouTube

    Afficher plus Afficher moins
    21 min
  • Daily, Sun 15 Nov: Beijing adds 107 drugs, Europe says yes. Who wins?
    Nov 14 2026

    Update, 15 Nov: after this episode was recorded, Summit Therapeutics said the FDA had issued a complete response letter for ivonescimab, so it is not approved in the US for now. We'll cover it in Monday's weekly.

    China's 2026 national reimbursement drug list adds 107 drugs, 51 of them Class 1 innovative, including the first CAR-T on the basic list, JW Therapeutics' (药明巨诺) relma-cel for lymphoma, from 1 January 2027. GLP-1 shots including Innovent's (信达生物) mazdutide are reimbursed for diabetes only; Novo Nordisk says China is the first country to reimburse its weekly insulin-semaglutide combination; Biokin's (百利天恒) iza-bren gets in for nasopharyngeal cancer; Akeso (康方生物) says ivonescimab was renewed at its original price. In the US, when we checked at 06:00 Singapore time Sunday, the FDA had not announced a decision on ivonescimab on its target day. Europe's CHMP backed two Chinese lung cancer drugs, Hansoh's (翰森制药) aumolertinib, seven weeks after the European Commission revoked its EU licence following a court challenge by AstraZeneca (the Commission acted before the court ruled), and Innovent's sintilimab. Plus China's new rules on blood and DNA samples leaving the country, and the US limits going the other way (our reading of the rules, not legal advice).

    Full transcript and all sources for this episode

    Both voices are AI-cloned. Basil Lui is the real person behind the show; Ning is an AI co-host. Personal views, not investment or medical advice. Basil holds no positions in any company mentioned.

    Chapters
    0:00 Intro and AI-voice disclosure
    0:47 China's 2026 drug list: 107 new drugs
    2:51 GLP-1s, Novo and iza-bren
    5:34 Ivonescimab: no FDA word yet
    6:41 Europe backs Hansoh and Innovent
    8:42 The biosample border
    11:08 What to watch and sign-off

    Key sources: NHSA: 2026 National Reimbursement Drug List release (official) · China Daily: CAR-T enters China's basic medical insurance list for first time · EMA: CHMP meeting highlights, 9–12 November 2026 · Xinhua: China issues revised rules on management of human genetic resources

    Weekly LinkedIn newsletter

    Also listen on: Apple Podcasts · Amazon Music · YouTube

    Afficher plus Afficher moins
    12 min
  • Daily, Sat 14 Nov: Can a Chinese cancer drug win over the FDA?
    Nov 14 2026

    This episode covers the FDA's target date for ivonescimab, a lung cancer bispecific invented by Akeso (康方生物) and licensed to Summit Therapeutics. The global HARMONi trial met its goal on progression-free survival (hazard ratio 0.52) but missed overall survival at the main analysis (hazard ratio 0.79); a later look showed a hazard ratio of 0.76, labelled nominal. Roughly six in ten patients were enrolled in Asia. When we checked early on Saturday morning, Singapore time, neither the companies nor the FDA had announced a decision. Also: Intellia's lonvo-z, a one-time in-body CRISPR treatment for hereditary angioedema, with a 10 March 2027 FDA date, and Argo Biopharma's (舶望制药) RNA silencer BW-20805 against the same protein. Windward Bio priced its Nasdaq offering at US$17 a share, expecting to raise about US$225 million including a Sanofi placement, for two China-licensed airway drugs that are not yet approved.

    Full transcript and all sources for this episode

    Both voices are AI-cloned. Basil Lui is the real person behind the show; Ning is an AI co-host. Personal views, not investment or medical advice.

    Chapters
    0:00 Intro and AI-voice disclosure
    0:47 Ivonescimab's FDA decision day
    1:58 The HARMONi trial results
    3:06 The East-West patient split
    3:47 Akeso's story
    5:01 What each outcome would mean
    5:38 BioNTech and a rival route
    6:33 Lonvo-z and in-body CRISPR
    7:41 Argo's RNA silencer
    8:24 Windward Bio's China-licensed IPO
    9:37 What to watch and sign-off

    Key sources: Summit Therapeutics: Q3 2026 results and ivonescimab PDUFA date (company press release) · Summit Therapeutics: updated HARMONi overall survival data at WCLC 2026 (company press release) · Nature: Novel CRISPR therapy is poised to gain first FDA approval to alter genes inside the body · Windward Bio: announces pricing of initial public offering (company press release)

    Weekly LinkedIn newsletter

    Also listen on: Apple Podcasts · Amazon Music · YouTube

    Afficher plus Afficher moins
    11 min
  • Daily, Fri 13 Nov: The first personalised mRNA cancer vaccine to succeed in Phase 3
    Nov 12 2026

    Basil Lui (linkedin.com/in/basillui) and Ning discuss Moderna and Merck's personalised mRNA cancer vaccine intismeran autogene (mRNA-4157/V940) plus Keytruda, the first positive Phase 3 result for a personalised neoantigen therapy, published in the New England Journal of Medicine: two-year recurrence-free survival of 82.2% versus 70.0% after surgery for high-risk melanoma. The vaccine is not approved, and overall survival has not been shown. Also: BioNTech's US$205 million priority review voucher; Reuters reporting, citing six sources, that the FDA has shelved the commissioner's national priority voucher pilot, which the health department says is ongoing; and China's approval of Lilly's weight-loss pill orforglipron. Beyond the clinic: India's Temple wearable, sold as a wellness device, and how the US and Singapore draw the medical-device line.

    Full transcript and all sources for this episode

    Both voices are AI-cloned. Basil Lui is the real person behind the show; Ning is an AI co-host. Personal views, not investment or medical advice.

    Chapters
    0:00 Intro and AI-voice disclosure
    0:47 A personalised mRNA cancer vaccine
    2:05 Phase 3 results and what's next
    3:19 How the vaccine is made
    4:29 Bancel, Asia sites, Singapore
    6:19 BioNTech's priority review voucher
    7:21 FDA voucher pilot and orforglipron
    8:14 Temple and two rulebooks
    9:27 Apple, Whoop, peptides and HSA
    10:41 What to watch and sign-off

    Key sources: NEJM: intismeran autogene Phase 3 (INTerpath-001) · Moderna: recapping the Phase 3 INTerpath results (company recap) · BioNTech: priority review voucher (company statement) · Reuters: China approves Eli Lilly's weight-loss pill orforglipron

    Weekly LinkedIn newsletter

    Also listen on: Apple Podcasts · Amazon Music · YouTube

    Afficher plus Afficher moins
    12 min